Literature DB >> 34345931

Sex-specific effects of psychedelics on prepulse inhibition of startle in 129S6/SvEv mice.

Justin M Saunders1, Alaina M Jaster1,2, Hiba Z Vohra1, Mario de la Fuente Revenga1,3, Jennifer Jimenez1, Alberto Fernández-Teruel4, Jennifer T Wolstenholme2,5, Patrick M Beardsley2,6, Javier González-Maeso7.   

Abstract

BACKGROUND: Prepulse inhibition (PPI) of startle is a sensorimotor gating phenomenon perturbed in a variety of neuropsychiatric conditions. Psychedelics disrupt PPI in rats and humans, but their effects and involvement of the serotonin 5-HT2A receptor (5-HT2AR) in mice remain unexplored.
METHODS: We tested the effect of the psychedelic 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) (0.5 mg/kg, i.p.) on startle amplitude and %PPI in response to acoustic stimuli under up to four different experimental conditions that included changes in background and stimulus intensity, prepulse and pulse duration, and interstimulus interval in male and female 129S6/SvEv mice. We also evaluated the effect of the 5-HT2AR antagonist M100,907 (1 mg/kg, i.p.) on DOI-induced startle amplitude and %PPI, as well as the effect of the psychedelic LSD (0.24 mg/kg, i.p.) and the dopamine agonists apomorphine (5 mg/kg, s.c.) and SKF-82,958 (0.5 mg/kg, i.p.) in male 129S6/SvEv mice.
RESULTS: DOI altered startle amplitude with either pulse alone or prepulse + pulse presentations in all PPI conditions, and increased %PPI in three out of four PPI conditions in male mice - an effect that was prevented by M100,907. In female mice, DOI increased %PPI without affecting startle amplitude. %PPI was positively correlated with startle amplitude in males while being negatively correlated in female mice. In male mice, LSD also increased %PPI, although it did not affect startle amplitude, whereas apomorphine and SKF-82,958 induced decreases in %PPI.
CONCLUSION: Our findings highlight a distinct effect of the psychedelic DOI on PPI in 129S6/SvEv mice, suggesting 5-HT2AR-dependent PPI improvement in a paradigm-dependent and sex-dependent manner.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  G protein-coupled receptor (GPCR); Hallucinogens; Lysergic acid diethylamide (LSD); Prepulse inhibition (PPI); Psilocybin; Psychedelics; Psychopharmacology; Sensorimotor gating; Serotonin 5-HT2A receptor; Sex differences

Mesh:

Substances:

Year:  2021        PMID: 34345931     DOI: 10.1007/s00213-021-05913-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  49 in total

Review 1.  Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.

Authors:  Clint E Canal; Drake Morgan
Journal:  Drug Test Anal       Date:  2012-04-19       Impact factor: 3.345

2.  Auditory and visual prepulse inhibition in mice: parametric analysis and strain comparisons.

Authors:  L Aubert; D Reiss; A-M Ouagazzal
Journal:  Genes Brain Behav       Date:  2006-07       Impact factor: 3.449

3.  Knockout mice reveal opposite roles for serotonin 1A and 1B receptors in prepulse inhibition.

Authors:  S C Dulawa; C Gross; K L Stark; R Hen; M A Geyer
Journal:  Neuropsychopharmacology       Date:  2000-06       Impact factor: 7.853

4.  Regulation of sensorimotor gating of the startle reflex by serotonin 2A receptors. Ontogeny and strain differences.

Authors:  M Farid; Z A Martinez; M A Geyer; N R Swerdlow
Journal:  Neuropsychopharmacology       Date:  2000-12       Impact factor: 7.853

5.  Effects of strain and serotonergic agents on prepulse inhibition and habituation in mice.

Authors:  S C Dulawa; M A Geyer
Journal:  Neuropharmacology       Date:  2000-08-23       Impact factor: 5.250

6.  Initial characterization of behavior and ketamine response in a mouse knockout of the post-synaptic effector gene Anks1b.

Authors:  Rachel M Enga; Ann C Rice; Pamela Weller; Mark A Subler; Daiyoon Lee; Chelsea P Hall; Jolene J Windle; Patrick M Beardsley; Edwin J van den Oord; Joseph L McClay
Journal:  Neurosci Lett       Date:  2017-01-20       Impact factor: 3.046

7.  Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers.

Authors:  Anya K Bershad; Scott T Schepers; Michael P Bremmer; Royce Lee; Harriet de Wit
Journal:  Biol Psychiatry       Date:  2019-06-03       Impact factor: 13.382

8.  Automated quantification of head-twitch response in mice via ear tag reporter coupled with biphasic detection.

Authors:  Mario de la Fuente Revenga; Hiba Z Vohra; Javier González-Maeso
Journal:  J Neurosci Methods       Date:  2020-01-16       Impact factor: 2.390

9.  Schizophrenia risk gene CAV1 is both pro-psychotic and required for atypical antipsychotic drug actions in vivo.

Authors:  J A Allen; P N Yadav; V Setola; M Farrell; B L Roth
Journal:  Transl Psychiatry       Date:  2011-08-16       Impact factor: 6.222

10.  Fully automated head-twitch detection system for the study of 5-HT2A receptor pharmacology in vivo.

Authors:  Mario de la Fuente Revenga; Jong M Shin; Hiba Z Vohra; Kelsey S Hideshima; Matthew Schneck; Justin L Poklis; Javier González-Maeso
Journal:  Sci Rep       Date:  2019-10-03       Impact factor: 4.379

View more
  2 in total

1.  Effects of the 5-HT2A receptor antagonist volinanserin on head-twitch response and intracranial self-stimulation depression induced by different structural classes of psychedelics in rodents.

Authors:  Alaina M Jaster; Harrison Elder; Samuel A Marsh; Mario de la Fuente Revenga; S Stevens Negus; Javier González-Maeso
Journal:  Psychopharmacology (Berl)       Date:  2022-03-02       Impact factor: 4.530

2.  Effects of acute lysergic acid diethylamide on intermittent ethanol and sucrose drinking and intracranial self-stimulation in C57BL/6 mice.

Authors:  Lauri V Elsilä; Juliana Harkki; Emma Enberg; Alvar Martti; Anni-Maija Linden; Esa R Korpi
Journal:  J Psychopharmacol       Date:  2022-06-13       Impact factor: 4.562

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.